In a subgroup analysis for statin-induced myopathy, the CYP3A5*3 polymorphism showed a similar trend; patients with the CYP3A5*3/*3 showed a higher risk of myopathy after statin treatment compared to the CYP3A5*3 allele carriers, although it did not achieve a statistical significance (*3/*3 vs. *1/*1 + *1/*3; OR = 1.30; 95% CI = 0.96–1.75; I2 = 64%; Figure 3). Here, CYP3A5 is linked to myopathy.